Cullinan Therapeutics (CGEM) Common Equity (2020 - 2026)

Cullinan Therapeutics' Common Equity history runs 7 years deep, the most recent figure standing at $366.2 million for Q1 2026.

• On a quarterly basis, Common Equity fell 33.65% year-over-year to $366.2 million in Q1 2026; TTM through Mar 2026 was $366.2 million, a 33.65% decrease from a year earlier, with the FY2025 full-year figure at $408.7 million, down 30.76% from the prior year.
• Common Equity fell to $366.2 million in Q1 2026 per CGEM's latest filing, from $408.7 million in the prior quarter.
• Across five years, Common Equity topped out at $656.2 million in Q2 2024 and bottomed at $366.2 million in Q1 2026.
• The 5-year median for Common Equity is $492.1 million (2025), against an average of $507.3 million.
• Across the five-year window, Common Equity soared 33.92% in 2024 and tumbled 33.65% in 2026, its largest moves.
• Year by year, Common Equity stood at $535.0 million in 2022, then declined by 15.16% to $453.9 million in 2023, then surged by 30.06% to $590.3 million in 2024, then slumped by 30.76% to $408.7 million in 2025, then slipped by 10.41% to $366.2 million in 2026.
• Per Business Quant, the three latest CGEM Common Equity figures stand at $366.2 million (Q1 2026), $408.7 million (Q4 2025), and $451.4 million (Q3 2025).